Focal deletions of a promoter tether activate the IRX3 oncogene in T-cell acute lymphoblastic leukemia.

Address: Department of Haematology, University College London Cancer Institute, London, United Kingdom.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Department of Haematology, University College London Cancer Institute, London, United Kingdom.; VIB-KU Leuven Centre for Cancer Biology, Leuven, Belgium.; Department of Developmental Biology and Cancer, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.; Department of Experimental Medicine and Biomedicine, Hull York Medical School, University of York, York, United Kingdom.; Department of Biomolecular Medicine, Ghent University, Ghent, Belgium.; Department of Systems Biology and Engineering and Biotechnology Centre, Silesian University of Technology, Gliwice, Poland.; Department of Molecular and Clinical Genetics, Institute of Human Genetics, Polish Academy of Sciences, Poznan, Poland.; Department of Medicine, Medical Research Council Weatherall Institute of Molecular Medicine Centre for Computational Biology, University of Oxford, Oxford, United Kingdom.; Department of Pediatric Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA.; Department of Molecular, Cell and Cancer Biology, University of Massachusetts Chan Medical School, Worcester, MA.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.; Department of Haematology, University College London Cancer Institute, London, United Kingdom.; Department of Developmental Biology and Cancer, Great Ormond Street Institute of Child Health, University College London, London, United Kingdom.